Profile pacjentów, którzy mogą odnieść korzyści z zastosowania terapeutycznych dawek trazodonu w leczeniu depresji Opis przypadku
##plugins.themes.bootstrap3.article.sidebar##
Opublikowane:
maj 31, 2026
Słowa kluczowe:
depresja, trazodon, SSRI
##plugins.themes.bootstrap3.article.main##
Abstrakt
Skuteczne leczenie depresji z użyciem trazodonu wymaga stosowania dawek terapeutycznych powyżej 150 mg (najczęściej w zakresie 225–300 mg), które odpowiadają zakresowi pełnego działania przeciwdepresyjnego. Formulacja XR zapewnia stabilne stężenia leku, dobrą tolerancję i wygodne dawkowanie raz na dobę, co sprzyja adherencji i długoterminowemu leczeniu. W artykule przedstawiono profile pacjentów, u których zastosowanie terapeutycznych dawek trazodonu XR w ramach monoterapii depresji jest szczególnie uzasadnione. Do tej grupy zalicza się m.in. seniorów z depresją maskowaną i wielolekowością, osoby aktywne zawodowo, młodych dorosłych z nasilonym napięciem i zaburzeniami snu, pacjentów z drażliwością i napadami złości, pacjentów z chorobami współistniejącymi oraz chorych wymagających szczególnej ostrożności w leczeniu ze względu na obciążenia kardiologiczne lub neurologiczne. Wspólnym mianownikiem tych profili jest potrzeba takiego leczenia depresji, które obejmuje nie tylko nastrój, lecz także sen, lęk, napięcie i funkcjonowanie, przy jednoczesnym ograniczeniu polipragmazji i ryzyka działań niepożądanych. Celem pracy jest zwrócenie uwagi na kliniczne znaczenie właściwego dawkowania trazodonu XR oraz na rolę indywidualizacji leczenia depresji na podstawie dominujących objawów, obciążeń somatycznych i oczekiwań funkcjonalnych pacjentów.
##plugins.themes.bootstrap3.article.details##
Jak cytować
Dudek, D. (2026). Profile pacjentów, którzy mogą odnieść korzyści z zastosowania terapeutycznych dawek trazodonu w leczeniu depresji. Medycyna Faktów , 19(1(70), 122-133. https://doi.org/10.24292/01.MF.0126.17
Numer
Dział
Artykuły
Copyright by Medical Education. All rights reserved.
Bibliografia
1. Dudek D. Trazodon jako lek pierwszego rzutu w leczeniu depresji. Znaczenie badania TED, danych randomizowanych i współczesnych rekomendacji. Medycyna Faktów 2025; 18(4).
2. Stahl SM. Mechanism of action of trazodone: a multifunctional drug. CNS Spectr. 2009; 14(10): 536-46.
3. Sheehan DV, Croft HA, Gossen ER et al. Extended-release trazodone in major depressive disorder: a randomized, double-blind, placebo-controlled study. Psychiatry (Edgemont). 2009; 6(5): 20-33.
4. Dudek D, Chrobak AA, Krupa AJ et al. TED-trazodone effectiveness in depression: a naturalistic study of the effectiveness of trazodone in extended release formulation compared to SSRIs in patients with a major depressive disorder. Front Pharmacol. 2023; 14: 1296639.
5. Shahpesandy H. Different manifestation of depressive disorder in the elderly. Neuro Endocrinol Lett. 2005; 26(6): 691-5.
6. Fernandez-Rodrigues V, Sanchez-Carro Y, Lagunas LN et al. Risk factors for suicidal behaviour in late-life depression: A systematic review. World J Psychiatry. 2022; 12(1): 187-203.
7. Beghi M, Butera E, Cerri CG et al. Suicidal behaviour in older age: A systematic review of risk factors associated to suicide attempts and completed suicides. Neurosci Biobehav Rev. 2021; 127: 193-211.
8. Wichniak A, Bieńkowski P, Dąbrowski R et al. Leczenie bezsenności osób w starszym wieku. Zalecenia Polskiego Towarzystwa Badań nad Snem, Polskiego Towarzystwa Medycyny Rodzinnej i Polskiego Towarzystwa Psychiatrycznego. Psychiatr Pol. 2023; 57(3): 495-516.
9. Varghese D, Ishida C, Patel P et al. Polypharmacy. StatPearls [Internet], 2024.
10. Fagiolini A, Pinto AG, Woznica Miskowiak K et al. Trazodone in the Management of Major Depression Among Elderly Patients with Dementia: A Narrative Review and Clinical Insights. Neuropsychiatr Dis Treat. 2023; 19: 2817-283.
11. Cuomo A, Bianchetti A, Cagnin A et al. Trazodone: a multifunctional antidepressant. Evaluation of its properties and real-world use. Journal of Gerontology and Geriatrics. 2021; 69: 120-29.
12. Rivasi G, Capacci M, Del Re LM et al. Trazodone and Risk of Orthostatic Hypotension, Syncope and Falls in Geriatric Outpatients with Hypertension. Observational Study Drugs Aging. 2025; 42(4): 373-80.
13. Zhou S, Li P, Lv X et al. Adverse effects of 21 antidepressants on sleep during acute-phase treatment in major depressive disorder: a systemic review and dose-effect network meta-analysis. Sleep. 2023; 46(10): zsad177.
14. Rothmore J. Antidepressant-induced sexual dysfunction. Med J Aust. 2020; 212(7): 329-34.
15. Goodwin GM, Price J, De Bodinat C et al. Emotional blunting with antidepressant treatments: A survey among depressed patients. J Affect Disord. 2017; 221: 31-5.
16. Siwek M, Chrobak AA, Dudek D et al. Trazodone effectiveness in depression: impacts of trazodone extended release vs SSRIs on the health status and quality of life of patients with major depressive disorder. Front Pharmacol. 2024; 15: 1525498.
17. Sinclair LI, Christmas DM, Hood SD et al. Antidepressant-induced jitteriness/anxiety syndrome: systematic review. BMJ. 2009; 339: b4736.
18. Baldwin DS, Foong T. Antidepressant drugs and sexual dysfunction. Br J Psychiatry. 2013; 202(6): 396-7.
19. Price J, Cole V, Goodwin GM. Emotional blunting with antidepressant treatments: a survey among depressed patients. J Affect Disord. 2009; 117(1-2): 91-5.
20. Read J, Cartwright C, Gibson K. Adverse emotional and interpersonal effects reported by 1829 New Zealanders while taking antidepressants. Soc Psychiatry Psychiatr Epidemiol. 2014; 49(10): 1569-78.
21. Fagiolini A, Albert U, Maina G et al. Role of trazodone in the treatment of major depressive disorder: a narrative review. Ann Gen Psychiatry. 2023; 22: 27.
22. Montejo AL, Llorca G, Izquierdo JA et al. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study. J Sex Marital Ther. 2001; 27(2): 111-23.
23. Fava M, Hwang I, Rush AJ et al. The importance of irritability as a symptom of major depressive disorder: results from the National Comorbidity Survey Replication. J Clin Psychiatry. 2010; 71(12): 1594-602.
24. Fava M, Mischoulon D. Anger, hostility, and irritability in major depressive disorder. CNS Spectr. 2016; 21(2): 95-102.
25. Read JR, Sharpe L, Modini M et al. Multimorbidity and depression: A systematic review and meta-analysis. J Affect Disord. 2017; 221: 36-46.
26. Jeffery A, Bhanu C, Walters K et al. Polypharmacy and antidepressant acceptability in comorbid depression and type 2 diabetes: a cohort study using UK primary care data. Br J Gen Pract. 2023; 73(730): e392-8.
27. Yuan Y, Tsoi K, Hunt RH. Selective serotonin reuptake inhibitors and risk of upper GI bleeding: confusion or confounding? Am J Med. 2006; 119(9): 719-27.
28. Gheysens T, Van Den Eede F, De Picker L. The risk of antidepressant-induced hyponatremia: A meta-analysis of antidepressant classes and compounds. Eur Psychiatry. 2024; 67(1): e20.
29. Dołoto A, Bąk E, Batóg G et al. Interactions of antidepressants with concomitant medications-safety of complex therapies in multimorbidities. Pharmacol Rep. 2024; 76(4): 714-39.
30. Siwek M. Dekalog leczenia depresji. ITEM Publishing, Warszawa 2024.
31. Glassman AH, O’Connor CM, Califf RM et al. Sertraline Treatment of Major Depression in Patients With Acute Myocardial Infarction or Unstable Angina: The SADHART Randomized Trial. JAMA. 2002; 288(6): 701-9.
32. Aarsland D, Påhlhagen S, Ballard CG et al. Depression in Parkinson disease – epidemiology, mechanisms and management. Nat Rev Neurol. 2011; 8(1): 35-47.
33. Seppi K, Weintraub D, Coelho M et al. The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the Non-Motor Symptoms of Parkinson’s Disease. Mov Disord. 2011; 26 (03): S42-80.
34. Frenklach A. Management of Depression in Parkinson’s Disease. Am J Psychiatry Resid J. 2016; 11(4): 8-11.
35. Panisset M, Chen JJ, Rhyee SH et al.; STACCATO study investigators: Serotonin toxicity association with concomitant antidepressants and rasagiline treatment: retrospective study (STACCATO). Pharmacotherapy. 2014; 34(12): 1250-8.
2. Stahl SM. Mechanism of action of trazodone: a multifunctional drug. CNS Spectr. 2009; 14(10): 536-46.
3. Sheehan DV, Croft HA, Gossen ER et al. Extended-release trazodone in major depressive disorder: a randomized, double-blind, placebo-controlled study. Psychiatry (Edgemont). 2009; 6(5): 20-33.
4. Dudek D, Chrobak AA, Krupa AJ et al. TED-trazodone effectiveness in depression: a naturalistic study of the effectiveness of trazodone in extended release formulation compared to SSRIs in patients with a major depressive disorder. Front Pharmacol. 2023; 14: 1296639.
5. Shahpesandy H. Different manifestation of depressive disorder in the elderly. Neuro Endocrinol Lett. 2005; 26(6): 691-5.
6. Fernandez-Rodrigues V, Sanchez-Carro Y, Lagunas LN et al. Risk factors for suicidal behaviour in late-life depression: A systematic review. World J Psychiatry. 2022; 12(1): 187-203.
7. Beghi M, Butera E, Cerri CG et al. Suicidal behaviour in older age: A systematic review of risk factors associated to suicide attempts and completed suicides. Neurosci Biobehav Rev. 2021; 127: 193-211.
8. Wichniak A, Bieńkowski P, Dąbrowski R et al. Leczenie bezsenności osób w starszym wieku. Zalecenia Polskiego Towarzystwa Badań nad Snem, Polskiego Towarzystwa Medycyny Rodzinnej i Polskiego Towarzystwa Psychiatrycznego. Psychiatr Pol. 2023; 57(3): 495-516.
9. Varghese D, Ishida C, Patel P et al. Polypharmacy. StatPearls [Internet], 2024.
10. Fagiolini A, Pinto AG, Woznica Miskowiak K et al. Trazodone in the Management of Major Depression Among Elderly Patients with Dementia: A Narrative Review and Clinical Insights. Neuropsychiatr Dis Treat. 2023; 19: 2817-283.
11. Cuomo A, Bianchetti A, Cagnin A et al. Trazodone: a multifunctional antidepressant. Evaluation of its properties and real-world use. Journal of Gerontology and Geriatrics. 2021; 69: 120-29.
12. Rivasi G, Capacci M, Del Re LM et al. Trazodone and Risk of Orthostatic Hypotension, Syncope and Falls in Geriatric Outpatients with Hypertension. Observational Study Drugs Aging. 2025; 42(4): 373-80.
13. Zhou S, Li P, Lv X et al. Adverse effects of 21 antidepressants on sleep during acute-phase treatment in major depressive disorder: a systemic review and dose-effect network meta-analysis. Sleep. 2023; 46(10): zsad177.
14. Rothmore J. Antidepressant-induced sexual dysfunction. Med J Aust. 2020; 212(7): 329-34.
15. Goodwin GM, Price J, De Bodinat C et al. Emotional blunting with antidepressant treatments: A survey among depressed patients. J Affect Disord. 2017; 221: 31-5.
16. Siwek M, Chrobak AA, Dudek D et al. Trazodone effectiveness in depression: impacts of trazodone extended release vs SSRIs on the health status and quality of life of patients with major depressive disorder. Front Pharmacol. 2024; 15: 1525498.
17. Sinclair LI, Christmas DM, Hood SD et al. Antidepressant-induced jitteriness/anxiety syndrome: systematic review. BMJ. 2009; 339: b4736.
18. Baldwin DS, Foong T. Antidepressant drugs and sexual dysfunction. Br J Psychiatry. 2013; 202(6): 396-7.
19. Price J, Cole V, Goodwin GM. Emotional blunting with antidepressant treatments: a survey among depressed patients. J Affect Disord. 2009; 117(1-2): 91-5.
20. Read J, Cartwright C, Gibson K. Adverse emotional and interpersonal effects reported by 1829 New Zealanders while taking antidepressants. Soc Psychiatry Psychiatr Epidemiol. 2014; 49(10): 1569-78.
21. Fagiolini A, Albert U, Maina G et al. Role of trazodone in the treatment of major depressive disorder: a narrative review. Ann Gen Psychiatry. 2023; 22: 27.
22. Montejo AL, Llorca G, Izquierdo JA et al. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study. J Sex Marital Ther. 2001; 27(2): 111-23.
23. Fava M, Hwang I, Rush AJ et al. The importance of irritability as a symptom of major depressive disorder: results from the National Comorbidity Survey Replication. J Clin Psychiatry. 2010; 71(12): 1594-602.
24. Fava M, Mischoulon D. Anger, hostility, and irritability in major depressive disorder. CNS Spectr. 2016; 21(2): 95-102.
25. Read JR, Sharpe L, Modini M et al. Multimorbidity and depression: A systematic review and meta-analysis. J Affect Disord. 2017; 221: 36-46.
26. Jeffery A, Bhanu C, Walters K et al. Polypharmacy and antidepressant acceptability in comorbid depression and type 2 diabetes: a cohort study using UK primary care data. Br J Gen Pract. 2023; 73(730): e392-8.
27. Yuan Y, Tsoi K, Hunt RH. Selective serotonin reuptake inhibitors and risk of upper GI bleeding: confusion or confounding? Am J Med. 2006; 119(9): 719-27.
28. Gheysens T, Van Den Eede F, De Picker L. The risk of antidepressant-induced hyponatremia: A meta-analysis of antidepressant classes and compounds. Eur Psychiatry. 2024; 67(1): e20.
29. Dołoto A, Bąk E, Batóg G et al. Interactions of antidepressants with concomitant medications-safety of complex therapies in multimorbidities. Pharmacol Rep. 2024; 76(4): 714-39.
30. Siwek M. Dekalog leczenia depresji. ITEM Publishing, Warszawa 2024.
31. Glassman AH, O’Connor CM, Califf RM et al. Sertraline Treatment of Major Depression in Patients With Acute Myocardial Infarction or Unstable Angina: The SADHART Randomized Trial. JAMA. 2002; 288(6): 701-9.
32. Aarsland D, Påhlhagen S, Ballard CG et al. Depression in Parkinson disease – epidemiology, mechanisms and management. Nat Rev Neurol. 2011; 8(1): 35-47.
33. Seppi K, Weintraub D, Coelho M et al. The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the Non-Motor Symptoms of Parkinson’s Disease. Mov Disord. 2011; 26 (03): S42-80.
34. Frenklach A. Management of Depression in Parkinson’s Disease. Am J Psychiatry Resid J. 2016; 11(4): 8-11.
35. Panisset M, Chen JJ, Rhyee SH et al.; STACCATO study investigators: Serotonin toxicity association with concomitant antidepressants and rasagiline treatment: retrospective study (STACCATO). Pharmacotherapy. 2014; 34(12): 1250-8.